Tag: NASDAQ:INSM

Finance

Investors Are Watching : Halliburton Company (NYSE:HAL), Insmed (NASDAQ:INSM), FactSet Research Systems (NYSE:FDS), Keurig Green Mountain, Inc. (NASDAQ:GMCR), Great Panther (NYSEMKT:GPL)

Halliburton Company (NYSE:HAL)‘s stock had its “neutral” rating reaffirmed by Zacks in a note issued to investors on Friday. They currently have a $71.00 target price on the stock. Zacks‘s target price indicates a potential upside of 5.01% from the stock’s previous close. Halliburton Company (NYSE:HAL) belongs to Basic Materials sector. Its net profit margin is 9.50% and weekly performance is 0.21%. On last trading … Continue reading Investors Are Watching : Halliburton Company (NYSE:HAL), Insmed (NASDAQ:INSM), FactSet Research Systems (NYSE:FDS), Keurig Green Mountain, Inc. (NASDAQ:GMCR), Great Panther (NYSEMKT:GPL)

Colin Pettis
Finance

Hot Biotech Movers: Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), Insmed Incorporated (NASDAQ:INSM), Gilead Sciences, Inc. (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) saw a significant decrease in short interest during the month of May. As of May 30th, there was short interest totalling 8,284,614 shares, a decrease of 15.5% from the May 15th total of 9,799,100 shares. Several analysts have recently commented on the stock. Analysts at Roth Capital downgraded shares of Chelsea Therapeutics International from a “buy” rating to a “neutral” … Continue reading Hot Biotech Movers: Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), Insmed Incorporated (NASDAQ:INSM), Gilead Sciences, Inc. (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Kristen Barton
Finance

Biotech Decliners: Insmed Incorporated (NASDAQ:INSM), 22nd Century Group Inc (NYSEMKT:XXII), Concert Pharmaceuticals Inc (NYSE:JMPC), Relypsa Inc (NASDAQ:RLYP)

Insmed Incorporated (NASDAQ:INSM) on May 13, 2014 announces that multiple posterpresentations reporting data on ARIKAYCE(TM), or liposomal amakacinfor inhalation, for the treatment of Pseudomonas aeruginosainfections in cystic fibrosis (CF) patients and for the treatment ofpatients with treatment-resistant nontuberculous mycobacterial (NTM)lung infections will be presented at the American Thoracic SocietyAnnual Meeting 2014, taking place May 16-21 in San Diego, California. Insmed Incorporated (NASDAQ:INSM) stock performance was … Continue reading Biotech Decliners: Insmed Incorporated (NASDAQ:INSM), 22nd Century Group Inc (NYSEMKT:XXII), Concert Pharmaceuticals Inc (NYSE:JMPC), Relypsa Inc (NASDAQ:RLYP)

Kevin Long
Finance

Biotech gainers: Insmed Incorporated (NASDAQ:INSM), Prothena Corporation (NASDAQ:PRTA), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Biota Pharmaceuticals (NASDAQ:BOTA)

Some days before, shares of Insmed Incorporated (NASDAQ:INSM) fell double digits after the company reported data on a 90 patient Phase 2 trial. Insmed Incorporated (NASDAQ:INSM) stock performance was 7.02% in last session and finished the day at $13.41. Traded volume was 1.55million shares in the last session and the average volume of the stock remained 788.23K shares. The beta of the stock remained 0.69. … Continue reading Biotech gainers: Insmed Incorporated (NASDAQ:INSM), Prothena Corporation (NASDAQ:PRTA), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Biota Pharmaceuticals (NASDAQ:BOTA)

John Bellich
Finance

Biotech Most Volatile: Celldex Therapeutics (NASDAQ:CLDX), Dyax Corp. (NASDAQ:DYAX), Insmed Incorporated (NASDAQ:INSM), Novavax (NASDAQ:NVAX)

Celldex Therapeutics Inc. (NASDAQ:CLDX) options contracts experienced a new 90-day record for call contracts where a total of 5,803 call contracts were traded in the busy trading session. The contract spread yielded a 0.58 put/call ratio where 1.7 call contracts were traded for each put contract. Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock performance was 0.07% in last session and finished the day at $13.73. Traded volume … Continue reading Biotech Most Volatile: Celldex Therapeutics (NASDAQ:CLDX), Dyax Corp. (NASDAQ:DYAX), Insmed Incorporated (NASDAQ:INSM), Novavax (NASDAQ:NVAX)

Chris Lewis
Finance

Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Earlier this week, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer’s (PFE – Analyst Report) Xalkori (crizotinib). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -1.16% in last session and finished the … Continue reading Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Jayne Crisman